Institute for Composite and Biomedical Materials, CNR, UOS of Pisa, Pisa, Italy.
J Mater Sci Mater Med. 2012 Jan;23(1):205-16. doi: 10.1007/s10856-011-4506-1. Epub 2011 Dec 6.
Over the past decade, a large number of strategies and technologies have been developed to reduce heart failure progression. Among these, cardiac tissue engineering is one of the most promising. Aim of this study is to develop a 3D scaffold to treat cardiac failure. A new three-block copolymer, obtained from δ-valerolactone and polyoxyethylene, was synthesised under high vacuum without catalyst. Copolymer/gelatine blends were microfabricated to obtain a ECM-like geometry. Structures were studied under morphological, mechanical, degradation and biological aspects. To prevent left ventricular remodelling, constructs were biofunctionalises with molecularly imprinted nanoparticles towards the matrix metalloproteinase MMP-9. Results showed that materials are able to reproduce the ECM structure with high resolution, mechanical properties were in the order of MPa similar to those of the native myocardium and cell viability was verified. Nanoparticles showed the capability to rebind MMP-9 (specific rebinding 18.67) and to be permanently immobilised on the scaffold surface.
在过去的十年中，已经开发出大量策略和技术来减缓心力衰竭的进展。其中，心脏组织工程是最有前途的方法之一。本研究旨在开发一种 3D 支架来治疗心力衰竭。我们合成了一种新的三嵌段共聚物，该共聚物由 δ-戊内酯和聚氧乙烯制成，在没有催化剂的情况下在高真空下进行。将共聚物/明胶共混物微加工以获得类似于细胞外基质的几何形状。从形态学、机械、降解和生物学方面研究了结构。为了防止左心室重构，我们通过分子印迹纳米颗粒对构建体进行了生物功能化，以针对基质金属蛋白酶 MMP-9。结果表明，这些材料能够以高分辨率复制细胞外基质结构，机械性能与天然心肌相似，并且细胞活力得到了验证。纳米颗粒显示出了结合 MMP-9 的能力（特异性结合 18.67），并可以永久固定在支架表面上。
